INTRAOCULAR-PRESSURE REDUCTION AND SYSTEMIC ABSORPTION OF TIMOLOL AFTER ADMINISTRATION OF ONE SIDE-COATED INSERTS IN RABBITS

被引:3
作者
SAETTONE, MF
CHETONI, P
CAPPANERA, L
CONTE, U
FINNE, U
JARVINEN, K
SALIVIRTA, J
URTTI, A
机构
[1] Laboratory of Pharmaceutical Technology, Laboratory of Pharmaceutical Biopharmaceutics, Institute of Pharmaceutical Chemistry, University of Pisa, Pisa
[2] Department of Pharmaceutical Chemistry, University of Pavia, Pavia
[3] Department of Pharmaceutical Technology, University ofKuopio, Kuopio
来源
JOURNAL OF OCULAR PHARMACOLOGY | 1993年 / 9卷 / 01期
关键词
D O I
10.1089/jop.1993.9.1
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The object of this study was to test whether flat, circular ophthalmic inserts releasing drug only from one side, would show improved activity parameters and reduced systemic absorption. To this purpose, uncoated and one-side coated hydroxypropylcellulose inserts containing timolol were prepared and evaluated. An acrylic copolymer (Eudragit(R) RS) was used as coating material. Timolol release from inserts was studied both in vitro and in vivo. Timolol release in vitro from the coated inserts was much slower than from the uncoated ones, due to the smaller releasing surface area. Compared with timolol eyedrops (0.5%, 50 mul), administration of 250 mug of timolol in uncoated or coated inserts produced a significantly greater hypotensive effect at 6 and 8 hr post instillation in rabbits with artificially increased intraocular pressure. The coated inserts containing 62.5 mug of timolol antagonised isoproterenol-induced ocular hypotension significantly more than timolol eyedrops (0.5%, 12.5 mul) and uncoated inserts containing 62.5 mug of timolol. Both uncoated and coated inserts provided a significant sustaining of timolol release in tear fluid and decreased systemic peak concentrations of timolol with respect to the eyedrop control. However, one-side coated inserts failed to show significant improvements with respect to the uncoated samples.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 18 条
[1]  
Shell J.W., Ophthalmic drug delivery systems, Surv. Ophthalmol., 29, pp. 117-128, (1984)
[2]  
Urtti A., Pipkin J.D., Rork G., Sendo T., Finne U., Repta A.J., Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits, Int. J. Pharm., 61, pp. 241-249, (1990)
[3]  
Finne U., Vaisanen V., Urtti A., Modification of ocular and systemic absorption of timolol from ocular inserts by a buffering agent and a vasoconstrictor, Int. J. Pharm., 65, pp. 19-27, (1990)
[4]  
Nelson W.L., Fraunfelder F.T., Sills J.M., Arrowsmith J.B., Kuritsky J.N., Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985, Am. J. Ophthalmol., 102, pp. 606-611, (1986)
[5]  
Salminen L., Review: systemic absorption of topically applied ocular drugs in humans, J. Ocul. Pharmacol., 6, pp. 243-249, (1990)
[6]  
Chang S.C., Lee V.H.L., Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: implications in the design of strategies to maximize the ratio of ocular to systemic absorption, J. Ocul. Pharmacol., 3, pp. 159-169, (1987)
[7]  
Lee V.H.L., Review: new directions in the optimization of ocular drug delivery, J. Ocul. Pharmacol., 6, pp. 157-164, (1990)
[8]  
Urtti A., Salminen L., Miinalainen O., Systemic absorption of ocular pilocarpine is modified by polymer matrices, Int. J. Pharm., 23, pp. 147-161, (1985)
[9]  
Saettone M.F., Chetoni P., Torracca M.T., Giannaccini B., Naber L., Conte U., Sangalli M.E., Gazzaniga A., Application of the compression technique to the manufacture of pilocarpine ophthalmic inserts, Acta Pharm. Technol., 36, pp. 15-19, (1990)
[10]  
Bonomi L., Perfetti S., Noya E., Bellucci R., Tomazzoli L., Experimental corticosteroid ocular hypertension in the rabbit, Graefes Arch. Klin. Exp. Ophthalmol., 209, pp. 73-82, (1978)